产品
编 号：F016809
分子式：C26H33NO6
分子量：455.54
分子式：C26H33NO6
分子量：455.54
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
257
In-stock
10mg
412
In-stock
50mg
960
In-stock
100mg
1520
In-stock
200mg
2320
In-stock
结构图
CAS No: 103890-78-4
产品详情
生物活性：
Lacidipine is an orally active and highly selective L-type calcium channel blocker that acts on smooth muscle calcium channels, primarily dilates peripheral arteries, reduces peripheral resistance, and has long-lasting anti-hypertensive activity. Lacidipine protects HKCs from apoptosis induced by ATP depletion and recovery by modulating the caspase-3 pathway. Lacidipine can be used in studies of hypertension, atherosclerosis and acute kidney injury (AKI).
体内研究：
Lacidipine (0.3, 1.0, 3.0 mg/kg; p.o.; single daily for 10 weeks) shows anti-atherogenic effects in the apoE-deficient mouse, and reduces plasma endothelin concentrations.Animal Model:Female C57BL/6 mice (Homozygous; apoE-deficient; atherosclerosis model).
Dosage:0.3, 1.0, 3.0 mg/kg
Administration:Oral gavage; single daily for 10 weeks.
Result:Induced a significant dose-dependent decrease in plasma endothelin levels.Significantly reduced the mean lesion area in a dose-related manner by 10, 17 and 53% for 0.3, 1.0, 3.0 mg/kg, respectively.
体外研究：
Lacidipine (0.01-100 μM; 24 h) inhibits HKCs proliferation in vitro in a concentration-dependent manner.Lacidipine (0.01-100 μM; 24 h) protects HKCs against apoptosis induced by ATP depletion and recovery by regulating the caspase-3 pathway.
Lacidipine is an orally active and highly selective L-type calcium channel blocker that acts on smooth muscle calcium channels, primarily dilates peripheral arteries, reduces peripheral resistance, and has long-lasting anti-hypertensive activity. Lacidipine protects HKCs from apoptosis induced by ATP depletion and recovery by modulating the caspase-3 pathway. Lacidipine can be used in studies of hypertension, atherosclerosis and acute kidney injury (AKI).
体内研究：
Lacidipine (0.3, 1.0, 3.0 mg/kg; p.o.; single daily for 10 weeks) shows anti-atherogenic effects in the apoE-deficient mouse, and reduces plasma endothelin concentrations.Animal Model:Female C57BL/6 mice (Homozygous; apoE-deficient; atherosclerosis model).
Dosage:0.3, 1.0, 3.0 mg/kg
Administration:Oral gavage; single daily for 10 weeks.
Result:Induced a significant dose-dependent decrease in plasma endothelin levels.Significantly reduced the mean lesion area in a dose-related manner by 10, 17 and 53% for 0.3, 1.0, 3.0 mg/kg, respectively.
体外研究：
Lacidipine (0.01-100 μM; 24 h) inhibits HKCs proliferation in vitro in a concentration-dependent manner.Lacidipine (0.01-100 μM; 24 h) protects HKCs against apoptosis induced by ATP depletion and recovery by regulating the caspase-3 pathway.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备